Rituximab counteracts loss of tolerance in membranous nephropathy patients through NK-mediated Treg induction
Preprint
Abstract
Background: Membranous nephropathy (MN) is a chronic, autoimmune kidney disease characterized by an autoimmune response against podocyte-specific antigens, compromising renal functions. Few studies attempted to mechanistically describe how rituximab influences Th cells and whether this impacts on clinical outcome. Methods: Th cell profile of MN patients was characterized using peripheral blood mononuclear cell samples from a multi-centre, prospective clinical trial. Th cell subsets (Treg, Th17 and Th1) were measured by flow cytometry at baseline and after rituximab treatment during a two years follow-up. In vitro studies on fresh peripheral blood samples and isolated cell populations were performed to investigate the mechanisms through which rituximab induces Treg cells. Findings: Before rituximab treatment, MN patients had a Th17/Treg imbalance when compared to age-matched healthy donors (p=0.004). Responders had significantly higher proportions of Treg cells post-rituximab than non-responders (p=0.037). In vitro , rituximab treatment induced Treg cells when using peripheral blood samples from MN patients, however the induction was lost when isolated T cells were used instead of whole blood (p=0.02). Rituximab did not directly induce Treg cells but required a specific cellular environment composed by at least B and Natural Killer (NK) cells as observed by treating pooled T, B and NK cells. Finally, using complementation assays, we demonstrated that rituximab-mediated Treg induction relied on cytokines, mainly Transforming growth factor β (TGFβ), secreted by activated NK cells. Interpretation: Rituximab induces Treg through cytokines produced by NK cells probably during the mechanism of B cell depletion by antibody-dependent cell-mediated cytotoxicity. This mechanism could potentiate the likelihood of remission in MN patients by counteracting loss of immune tolerance.Keywords
This publication has 58 references indexed in Scilit:
- T cell phenotype switching in autoimmune disorders: Clinical significance of targeting metabolismClinical and Translational Medicine, 2022
- A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell MalignanciesAdvances in Therapy, 2016
- New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literatureAutoimmunity Reviews, 2016
- B cells expressing IFN‐γ suppress Treg‐cell differentiation and promote autoimmune experimental arthritisEuropean Journal of Immunology, 2015
- Th17 and regulatory T cell balance in autoimmune and inflammatory diseasesAutoimmunity Reviews, 2014
- T helper cells plasticity in inflammationCytometry Part A, 2013
- Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravisJournal of Neurology, 2013
- Rituximab-induced direct inhibition of T-cell activationCancer Immunology, Immunotherapy, 2012
- Depletion of functionally active CD20+ T cells by rituximab treatmentArthritis & Rheumatism, 2009
- Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLEClinical Immunology, 2007